GLPwatch

Development and characterization of exendin-4 loaded self-nanoemulsifying system and <i>in vitro</i> evaluation on Caco-2 cell line.

J Microencapsul · 2020

Last updated 2026-05-28

Researchers developed a drug delivery system for exendin-4, a GLP-1 drug, using a nanoemulsion that released 73.79% of the peptide over 2 hours in lab tests. The system improved the drug's ability to pass through intestinal cells compared to a standard solution, and tests showed it was not toxic to cells. The nanoemulsion had droplets smaller than 25 nanometers.

AI summary of the abstract below.

JournalJ Microencapsul, 2020
Citations5
Relative citation ratio0.50
NIH percentile29
Molecules
Conditions studied Type 2 Diabetes, Obesity

Abstract

Aim of this study was to develop exendin-4 and exendin-4/chymostatin loaded self-nanoemulsifying drug delivery system (SNEDDS). Surfactants and co-surfactants were mixed, oil phase containing exendin-4 or exendin-4/chymostatin was added dropwise for SNEDDS. Short term physical stability test was performed prior to the release, lipolysis and permeability studies. SNEDDS containing ethyl oleate: Cremophor EL: Labrasol: propylene glycole (15:42.5:21.25: 21.25) were selected for release and intestinal permeability studies for suitable parameters and physical stability test results. SNEDDS were obtained which yielded Grade B nanoemulsions having droplet size below 25 nm. release studies showed that 73.79% of the peptide was released for 2 h at pH 6.8. Both exendin-4 and exendin-4/chymostatin loaded SNEDDS were non-toxic to Caco-2 cells. Permeability coefficients of both exendin-4 loaded SNEDDS and exendin-4/chymostatin loaded SNEDDS were higher than exendin-4 solution. Intestinal permeability of exendin-4 has been improved by SNEDDS formulations.

Verbatim abstract via PubMed 31714163 ↗